Boston Therapeutics, Inc.

Boston Therapeutics, Inc. insiders are currently net buyers of BTHE stock, showing bullish sentiment over the past 90 days. Executives have purchased $642.6K while selling $80.0K, resulting in a positive net flow of $562.6K. This buying activity represents 89% of total transaction volume.

Boston Therapeutics, Inc. has 7 active insiders who have filed SEC Form 4 transactions in the past 90 days. Jonathan B. Rome (Executive) leads with 1 transactions totaling $625.0K. David Platt (Executive) follows with 37 transactions worth $51.9K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Boston Therapeutics, Inc.'s current score of 89/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $642.6K in purchases versus $80.0K in sales.

The most recent insider transaction occurred on May 15, 2015, when Platt David (Executive) acquired 1,000 shares at $0.15 per share for $150. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, BTHE insider trading sentiment is currently bullish with an Alignment Score of 89/100. The net insider flow of $562.6K reflects accumulation, with 89% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Boston Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At BTHE, we track all Form 4 filings—currently showing 43 transactions from 7 insiders over 90 days.

A 10b5-1 plan allows Boston Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At BTHE, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at BTHE appears discretionary, making insider signals more meaningful.

You can monitor Boston Therapeutics, Inc. (BTHE) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 7 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Boston Therapeutics, Inc.'s current score of 89/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $642.6K in purchases versus $80.0K in sales over 90 days, resulting in a net flow of $562.6K.

SEC Form 4 filings are mandatory reports that Boston Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At BTHE, the most common type is "P" with 39 occurrences. The most recent Form 4 was filed on May 15, 2015 by Platt David.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Boston Therapeutics, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at BTHE represents discretionary decisions with more informational value.